Thomas Reiberger's research while affiliated with Imperial College London and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (863)
Posthepatectomy liver failure (PHLF), complications of portal hypertension, and disease recurrence determine the outcome for hepatocellular carcinoma (HCC) patients undergoing liver resection. This study aimed to evaluate the von Willebrand factor antigen (vWF-Ag) as a non-invasive test for clinically significant portal hypertension (CSPH) and a pr...
Background
Previous experimental and clinical studies suggested a beneficial effect of statins, metformin, angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers (RASi) on portal hypertension. Still, their effects on hard cirrhosis-related clinical endpoints, such as variceal bleeding and bleeding-related mortality, remain to...
LINKED CONTENT
This article is linked to Hofer et al papers. To view these articles, visit https://doi.org/10.1111/apt.17908 and https://doi.org/10.1111/apt.18044.
Background and Aims
Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH‐related features on hepatic decompensation and transplant‐free survival in patients with Wilson's disease.
Methods and Results
About 137 patients with Wilson's disease...
LINKED CONTENT
This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18019 and https://doi.org/10.1111/apt.18036
CytoSorb is a hemoadsorptive column used to remove high concentrations of proinflammatory cytokines in septic shock. Data on CytoSorb application in acute-on-chronic liver failure (ACLF) is lacking. This retrospective observational study analyzed 21 ACLF patients admitted to ICUs at the Vienna General Hospital who received CytoSorb adsorber therapy...
Background
Obesity impacts the diagnostic accuracy of shear wave elastography (SWE). A deep abdominal ultrasound transducer (DAX) capable of point (pSWE) and two‐dimensional (2D)‐SWE has recently been introduced to address this issue.
Methods
We performed a prospective study in a cohort of mostly patients with obesity undergoing liver biopsy with...
LINKED CONTENT
This article is linked to Hofer et al papers. To view these articles, visit https://doi.org/10.1111/apt.17908 and https://doi.org/10.1111/apt.17924
Background and Aims
The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages of advanced chronic liver disease (ACLD). Therefore, we investigated the evolution of VWF and other biomarkers throughout the full ACLD spectrum and evaluated their stage‐specific prognostic utility.
Methods
We retrospectively included Vie...
Background & Aims
Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients with compensated disease. We aimed for the analysis of real-world data on the off-label use of bul...
Background & Aims
Compensated advanced chronic liver disease (cACLD) identifies patients at risk for clinically significant portal hypertension (CSPH), and thus, for liver-related complications. Limited availability of liver stiffness measurements (LSM) impedes the identification of patients at risk for cACLD/CSPH outside of specialized clinics. We...
Background
Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis.
Aims
We explored the potential for recompensation in patients with decompensated primary biliary cholangitis (PBC) – considering a biochemical response to ursodeoxycholic acid (UDCA) according to Paris‐II criteria as a surrogat...
Background and aims
Experimental studies linked dysfunctional Farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) signaling to liver disease. This study investigated key intersections of the FXR-FGF19 pathway along the gut–liver axis and their link to disease severity in patients with cirrhosis.
Methods
Patients with cirrhosis undergoin...
Persistent liver injury triggers a fibrogenic program that causes pathologic remodeling of the hepatic microenvironment (i.e., liver fibrosis) and portal hypertension. The dynamics of gene regulation during liver disease progression and early regression remain understudied. Here, we generated hepatic transcriptome profiles in two well-established l...
Background & aims
The value of bleeding prophylaxis and anticoagulation in patients with hepatocellular carcinoma (HCC) and macrovascular tumour invasion (MVI) is unclear. We evaluated the impact of anticoagulation on thrombosis progression, bleeding events, and overall mortality, and assessed the efficacy of adequate management of varices as recom...
Background & Aims
Patients with cirrhosis show alterations in primary haemostasis, yet prognostic implications of changes in platelet activation remain controversial and assay validity is often limited by thrombocytopenia. We aimed to study the prognostic role of platelet activation in cirrhosis, focusing on bleeding/thromboembolic events, decompen...
Background & Aims
Cholemic nephropathy (CN) is a severe complication of cholestatic liver diseases for which there is no specific treatment. We revisited its pathophysiology with the aim of identifying novel therapeutic strategies.
Methods
Cholestasis was induced by bile duct ligation (BDL) in mice. Bile flux in kidneys and livers was visualized b...
Background & Aims
Spontaneous portosystemic shunts (SPSS) develop frequently in cirrhosis. Changes over time and the effect of aetiological interventions on SPSS are unknown, so we aimed to explore the effect of these variables on SPSS evolution.
Methods
Patients with cirrhosis from the Baveno VI-SPSS cohort were selected provided a follow-up abdo...
Background & Aims
Advanced chronic liver disease (ACLD) may affect thyroid hormone homeostasis. We aimed to analyze the pituitary–thyroid axis in ACLD and the prognostic value of free triiodothyronine (fT3).
Methods
Patients with ACLD (liver stiffness measurement [LSM] ≥10 kPa) undergoing hepatic venous pressure gradient (HVPG) measurement between...
Background
Portal hypertension is a severe complication of cirrhosis. This Phase Ib study (NCT03842761) assessed the safety, tolerability, and pharmacokinetics of soluble guanylyl cyclase activator BI 685509 in patients with mild or moderate hepatic impairment (Child–Pugh [CP] A or B cirrhosis) and healthy volunteers (HVs).
Methods
In this single-...
Alcohol-related liver disease (ALD) is among the leading causes of liver-related mortality worldwide. Patients who progress to alcohol-related cirrhosis are at risk for developing portal hypertension (PH), a key pathophysiological driver of disease progression and hepatic decompensation. PH following chronic alcohol consumption develops as a conseq...
Background & Aims
Increased aggregation of individual platelets upon activation, as assessed by whole blood aggregometry standardised to platelet count (PLT), has recently been linked to progression of advanced chronic liver disease (ACLD). Moreover, changes in primary haemostasis have been implicated in bleeding and thrombosis in patients with ACL...
Background and aims
Micro-elimination projects targeted to specific hepatitis C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on already available laboratory records may represent an effective macroelimination approach to achieve global HCV elimination.
Met...
LINKED CONTENT
This article is linked to Paternostro et al papers. To view these articles, visit https://doi.org/10.1111/apt.17653 and https://doi.org/10.1111/apt.17673
LINKED CONTENT
This article is linked to Paternostro et al papers. To view these articles, visit https://doi.org/10.1111/apt.17653 and https://doi.org/10.1111/apt.17692
Background
Sarcopenia is a common problem in patients with HCC. We aimed to evaluate the prognostic and predictive value of baseline transversal psoas muscle thickness (TPMT) measurement in patients with HCC undergoing immunotherapy.
Methods
HCC patients treated with programmed death ligand 1–based therapies between June 2016 and October 2022 at t...
Introduction:
Liver cirrhosis accounts for considerable morbidity and mortality worldwide and late presentation limits therapeutic options. We aimed to assess characteristics of patients with liver cirrhosis at the time of first presentation and during their clinical course.
Methods:
Patients with cirrhosis as evident by presence of varices at e...
Background and aims
Endothelial dysfunction and portal hypertension (PH) are reflected by increased von Willebrand factor antigen (VWF-Ag) levels in advanced chronic liver disease (ACLD). This study investigated VWF release and cleavage and their association with PH and clinical outcomes.
Methods
Levels of VWF-Ag, VWF-N (VWF-propeptide), and VWF-A...
Background
Posthepatectomy liver failure (PHLF) contributes significantly to morbidity and mortality after liver surgery. Standardized assessment of preoperative liver function is crucial to identify patients at risk. These European consensus guidelines provide guidance for preoperative patient assessment.
Methods
A modified Delphi approach was us...
The expression of the receptor tyrosine kinase Axl and its cleavage product soluble Axl (sAxl) is increased in liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In this multicenter study, we evaluated the diagnostic value of Gas6, the high-affinity ligand of Axl, in patients with chronic liver disease. Levels of sAxl and Gas6, and thei...
Background & aim:
Glucagon like peptide (GLP)-2 may exert anti-fibrotic effects on hepatic stellate cells (HSCs). Thus, we aimed to test whether application of the GLP-2 analogue teduglutide has hepato-protective and anti-fibrotic effects in the Mdr2/Abcb4-/- mouse model of sclerosing cholangitis displaying hepatic inflammation and fibrosis.
Meth...
Background
Non‐selective betablockers (NSBBs) reduce the risk of hepatic decompensation in patients with compensated advanced chronic liver disease (cACLD). Metabolic co‐morbidities (MetC) are increasingly observed in cACLD patients.
Aims
To investigate the impact of MetC on the haemodynamic effects of NSBB and hepatic decompensation in cACLD.
Me...
Background and Aims Cirrhotic patients display an increased risk for both bleeding and thrombosis. We investigated platelet activation across Child–Pugh stages (CPSs) and portal hypertension (PH) severity.
Methods A total of 110 cirrhotic patients were prospectively included. CPS and hepatic venous pressure gradient (HVPG) were determined. Platelet...
Persistent liver injury triggers a fibrogenic program that causes pathologic remodelling of the hepatic microenvironment (i.e., liver fibrosis) and portal hypertension. The dynamics of gene regulation during liver disease progression and regression remain understudied. Here, we generated hepatic transcriptome profiles in two well-established liver...
Background & aims:
Removing the primary aetiological factor in decompensated cirrhosis may lead to a restoration of hepatic function. In this study, we investigated the clinical implications of recompensation and the subsequent survival in patients with decompensated alcohol-related cirrhosis.
Methods:
The rate of recompensation was evaluated in...
Background & aims:
Liver stiffness measurements (LSM) provide an opportunity to non-invasively monitor liver disease progression/regression. We aimed to determine the prognostic relevance of LSM-dynamics over time for liver-related events and death in patients with chronic liver disease.
Methods:
Patients with chronic liver disease undergoing ≥2...
Background:
Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT).
Methods:
OAT prescriptions were required monthly at one of nine approved authorities, making them ideal...
Background:
The diagnosis of clinically significant portal hypertension is crucial for prognosis and treatment guidance in patients with compensated advanced chronic liver disease (ACLD). Spleen stiffness measurement (SSM) might improve the non-invasive diagnosis of clinically significant portal hypertension, but previous studies have reported het...
Background and aims:
Heart failure (HF) might lead to increased hepatic venous pressure, thereby impairing hepatic blood outflow and subsequently inducing congestive hepatopathy. We aimed to evaluate prevalence of congestive hepatopathy in patients undergoing heart transplantation (HTX) as well as their post-transplant course.
Methods:
Patients...
The Billroth IV consensus was developed during a consensus meeting of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of Interventional Radiology (ÖGIR) held on the 26th of November 2022 in Vienna.
Based on international recommendations and considering recent landmark studies, the Billroth IV consensus provid...
Purpose:
This study evaluated ElastQ, a two-dimensional shear wave elastography (2D-SWE) technique, for the non-invasive assessment of liver fibrosis risk using liver stiffness measurement (LSM). The aim was to determine its diagnostic accuracy and establish LSM cutoffs for clinical risk stratification.
Methods:
A prospective multicenter study w...
Citations
... We read with great interest the recent article by Hofer et al. 1 This is the first research to explore recompensation in primary biliary cholangitis (PBC) patients, which demonstrates that hepatic recompensation may also occur in patients with decompensated PBC treated with ursodesoxycholic acid (UDCA) and suggests that biochemical ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1058581684174849-1629396949318_Q64/Benedikt-Hofer-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/749783572545536-1555773742116_Q64/Benedikt-Simbrunner.jpg)
... The SPP1 and THRSP genes have also been shown to be among the top 10 differentially expressed genes, in line with our previous research using thioacetamide liver injection in guinea pigs and rats [11]. In fact, SPP1 is an important biomarker for fibrosis [22]. FGF21 is another significant gene, and according to recent research, it plays a significant role in lipid metabolism and reduces hepatocyte damage [23][24][25][26][27]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281230873741-1711121606495_Q64/Oleksandr-Petrenko.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1087787600228417-1636360182676_Q64/Philipp-Koenigshofer.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/747864334553091-1555316160631_Q64/Ksenia-Brusilovskaya.jpg)
... Embora estas geralmente sejam assintomáticas, o sangramento é uma emergência com risco de vida e os sinais incluem hematêmese e hematoquezia devido à passagem de sangue pelo trato digestivo (Borgheresi et al., 2022). O diagnóstico é realizado por meio de endoscopia digestiva alta, juntamente com exames clínicos, de sangue e de imagem, no entanto é preconizado o protocolo de diagnóstico de cada serviço de saúde específico (Balcar et al., 2024). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1064341654736896-1630770233092_Q64/Lorenz-Balcar.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281184478486-1693380459948_Q64/Bernhard-Scheiner.jpg)
... Apart from LSM/SSM-based assessments, the von Willebrand factor antigen-to-platelet ratio (VITRO) appears to have similar prognostic performance as HVPG and the ANTICIPATE±NASH models in patients with cACLD (142). In a study of 420 patients, the incidence of hepatic decompensation at 1 year was 0% in patients with VITRO <2.5, compared with 10.4% in those with VITRO ≥2.5. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1057864856653825-1629226044595_Q64/Mathias-Jachs.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1097333622222849-1638636131561_Q64/Lukas-Hartl-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/934241575653378-1599751957273_Q64/Georg-Semmler.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281231069479-1711320713926_Q64/Mattias-Mandorfer.jpg)
... The other two cases of AIH-related SPSS involved a recanalized umbilical vein [17] and an intrahepatic SPSS [18], respectively. Moreover, the prevalence of SPSS increases over time in patients with cirrhosis, and hepatic function gradually worsens upon SPSS formation [22,23]. Specifically, Saad classified portosystemic shunt syndrome into three stages according to its natural disease course [12]. ...
... Bile acid transporters in the kidney also play a critical role in the systemic circulation of bile acids, particularly when the enterohepatic circulation of bile acids is disrupted [28]. The kidney functions as an alternative pathway for bile acid excretion when the bile flow from the liver to the intestine is impaired. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281102986419-1669579012713_Q64/Ahmed-Ghallab-3.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1119499189268481-1643920814512_Q64/Daniela-Gonzalez-Leiva.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272453339447317-1441969346658_Q64/Ute-Hofmann.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272715449892900-1442031838652_Q64/Jan-Hengstler.jpg)
... Nevertheless, transient reductions in BP followed by a compensatory HR increase from baseline confirmed on-target cardiovascular effects for BI 685509. However, the focus of the current study was safety and tolerability, and, based on our findings in this trial, specific PD effects of the following doses of BI 685509 (after uptitration according to individual tolerability) were evaluated in subsequent studies: 1.0 mg to 3.0 mg bid in the 1366.20 Phase Ib trial in people with mild and moderate hepatic impairment (NCT03842761) (Lawitz et al. 2023); 3.0 mg qd, or 1.0 mg or 3.0 mg tid, in the 1366.04 Phase Ib trial in people with diabetic kidney disease (NCT03165227) (Cherney et al. 2023). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/672914105974784-1537446633588_Q64/Eric-Lawitz-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272164662280218-1441900520351_Q64/Joern-Schattenberg.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/806934471008265-1569399578732_Q64/Corinna-Schoelch.jpg)
... In a Chinese study involving TKIs (LEN or sorafenib) plus a combination of ICIs, patients with sarcopenia at baseline experienced a reduced OS and an increased disease progression compared to patients without it in all regimen choices [123]. A European study conducted on patients treated with various anti-PDL1 regimens confirmed that sarcopenia negatively affected OS, especially in patients with higher systemic inflammation activation [124]. On the other hand, in camrelizumab-treated patients, sarcopenia was related to lower PFS but not to a lower OS, even if a trend toward lower OS in sarcopenic individuals was observed [125]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/637464309936142-1528994743696_Q64/Katharina-Lampichler.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/671895607316483-1537203804525_Q64/Lucian-Beer.jpg)
... Knowledge gained by probing molecular aberrations in liver diseases like PBC and cirrhosis can ultimately inform management strategies. 12 Another active hepatology research area involves optimizing care delivery through screening and risk stratification. For example, growing recognition exists that metabolic-associated fatty liver disease (MAFLD) can manifest in childhood and cause substantial morbidity if untreated. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1120880751054854-1644250204751_Q64/Rafael-Paternostro.jpg)
... While perioperative innovations have helped to push borders in hepatobiliary surgery, resections are still mainly limited by the function and volume of the liver remaining in situ, referred to as the future liver remnant (FLR) [20][21][22]. In the case of an insufficient FLR, potentially life-threatening postoperative liver dysfunction ("post-hepatectomy liver failure"/PHLF) can occur, often associated with secondary co-factors such as infections or bleeding. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/358138537627653-1462398289968_Q64/Florian-Primavesi.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/304378823544832-1449580974309_Q64/Federica-Cipriani.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/988525637931008-1612694286433_Q64/Stefan-Staettner.jpg)
